---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-230925"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:35:23.842076+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics appoints Ian F. Smith as permanent CEO; interim role since March 2025

## Summary
- Ian F. Smith, 59, appointed CEO effective Oct 6, 2025; served as interim CEO since March 19, 2025.
- Annual base salary of $715,000; eligible for annual bonus target of 65% of base salary (no 2025 bonus).
- Receives $500,000 sign-on bonus (repayable if resigns within 12 months) and $500,000 performance bonus based on metrics.
- Equity grant: option for 570,000 shares (4-yr vest) and RSU for 380,000 shares (4-yr annual vest).
- Dr. Tzianabos resigns as Interim Executive Chair, resumes as independent director and Chair of the Board.

## SEC filing metadata
- accession: 0001193125-25-230925
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312525230925/0001193125-25-230925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312525230925/d55930d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-230925
- JSON: https://secwatch.observer/filing/0001193125-25-230925.json
- Plain text: https://secwatch.observer/filing/0001193125-25-230925.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.